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Interaction of tamoxifen with the multidrug resistance P-glycoprotein
R Callaghan and CF Higgins
Imperial Cancer Research Fund Laboratories, Institutefor Molecular Medicine, and Nuffield Department of Clinical Biochemistry,
University ofOxford, John Radcliffe Hospital, Oxford OX3 9DU, UK.
S.m.ary Tamoxifen is an anti-oestrogen which is currently being assessed as a prophylactic for women at
high nrsk of breast cancer. Taxoxifen has also been shown to reverse multidrug resistance in P-glycoprotein
(P-gp)-expressing cells, although the mechanisim of action is unknown. In this study we demonstrate that
tamoxifen interacts directly with P-gp. Plasma membranes from P-gp-expressing cells bound [3HJtamoxifen in a
specific and saturable fashion. A 180 kDa membrane protein in these membranes, labelled by the affinity
analogue tamoxifen aziridine and azidopine, was shown to be P-gp. Tamoxifen reduced the binding of
vinblastine and azidopine to P-gp, and tamoxifen increased [3H]vinblastine accumulation in P-gp-expressing
cells to levels approaching those in non-P-gp-expressing cells. However, the cellular accumulation of
[3Hltamoxifen itself was not influenced by the presence of P-gp. Thus, tamoxifen appears to reverse multidrug
resistance by binding to P-gp and inhibiting the transport of cytotoxic drugs. but does not itself appear to be
transported by the protein.
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Tamoxifen is an anti-oestrogen which displays tumoristatic
properties (Lerner and Jordan, 1990). The use of tamoxifen
in the clinic has progressed from palliation in advanced
breast cancer (Jordan, 1990, 1992; Lerner and Jordan, 1990)
to efficacious treatment of all stages of oestrogen receptor-
positive breast cancer. Furthermore, tamoxifen is currently
being assessed as a prophylactic agent for women at high risk
of developing breast cancer (Jordan, 1990). Tamoxifen acts
by binding to the cytosolic oestrogen receptor (Katzenellen-
bogen et al., 1983; Berthois et al., 1986) and inhibiting the
binding of oestrogens (Jordan and Prestwich, 1977; Jordan
and Naylor, 1979). Tamoxifen is tolerated to high doses and
has few reported side-effects owing to its high target
specificity (Jordan. 1992).
Tamoxifen has also been demonstrated to reverse the drug
resistance phenotype of several P-glycoprotein (P-gp)-
expressing cell lines (Ramu et al., 1984; DeGregorio et al..
1989; Kirk et al., 1993a,b). However, it is not known whether
this is an indirect effect or the result of the direct interaction
of tamoxifen with P-gp. P-gp is frequently associated with
the phenomenon of multidrug resistance (MDR) (Kartner et
al., 1983), acting as an ATP-dependent, drug efflux pump to
reduce the intracellular accumulation of antineoplastic drugs
(Inaba et al., 1979; Cornwell et al.. 1986a; for reviews see
also Riordan and Ling 1985; Honio et al., 1988; Gottesman
and Pastan, 1993). A number of compounds are known to
antagonise the drug efflux activity of P-gp, such as verapamil
and other calcium channel blockers, immunosuppressants
(e.g. cyclosporin A), antiarrhythmics and antihistamines (for
review see Gottesman and Pastan, 1993). Many of these
compounds bind to P-gp and are believed to reverse drug
resistance by competing with drug binding to and/or drug
transport (Wigler and Patterson, 1993). Thus, it seemed pos-
sible that tamoxifen might also interact directly with P-gp. In
this study we demonstrate that tamoxifen does indeed bind
to P-gp and inhibits the transport of cytotoxic drugs,
although it does not appear to be a substrate for transport.
This identifies a second target for tamoxifen in certain tissues
and has implications for the therapeutic use of tamoxifen.
Materia and methods
Chemicals
[3HjVinblastine sulphate (11 Cimmol-'), [3HJazidopine
(52 Ci mmol '), [3Hltamoxifen (84 Ci mmol-') and [3H1tamo-
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xifen aziridone (24 Cimmol-') were purchased from Amer-
sham Life Sciences (Amersham. UK). Vinblastine sulphate.
tamoxifen and protein A-Sepharose were obtained from
Sigma Chemicals. The monoclonal antibody against P-gp
(C219) was purchased from Centocor Diagnostics. Tissue
culture reagents were provided by the ICRF Clare Hall
Laboratory.
Cell culture
The human epidermal carcinoma cell line KB3- and its
drug-resistant derivative KBV-1 were provided by Dr M
Gottesman (Shen et al.. 1986). Cells were grown in Dulbec-
co's modified Eagle medium (DMEM) containing 10% fetal
bovine serum (FBS) and supplemented with penicillin and
streptomycin. The KBV-1 cell line was maintained in medium
which also contained 1 ,.g ml-' vinblastine. The level of resis-
tance displayed by KBV-1 cells to vinblastine, colchicine and
adriamycin was 213-, 171- and 422-fold respectively (Shen et
al.. 1986).
Plasma membrane isolation
Plasma membrane fractions were isolated according to pre-
viously published methods (Cornwell et al., 1986b). Disrup-
tion of cells (5 x 10k) was achieved by nitrogen cavitation
(1500 p.s.i.. 20 min). All buffers contained the following pro-
tease inhibitors: phenylmethylsulphonyl fluoride (PMSF)
1 mM. benzamidine I mM. aprotinin 1 gg ml-' and EDTA
I mM. Membranes were snap frozen in liquid nitrogen and
stored in 0.01 M Tnrs-HCI pH 7.4, 0.25 M sucrose, at - 70°C.
The protein concentration of each sample was determined by
a micro-Lowry assay using bovine serum albumin as a stan-
dard.
Affinity labelling ofplasma membranes
Photoaffinity labelling of membranes with [3H]azidopine was
done according to previously published methods (Safa et al..
1987). Briefly, membranes (40ILg) were incubated in labelling
buffer (0.01 M Tris-HCI pH 7.4, 0.25 M sucrose, 5 mM mag-
nesium chloride) containing 45 nM (3Hlazidopine. Tamoxifen
(1. 10. 50 or 100jM). verapamil (50 M) or vinblastine
(5011M) was used to compete with [3Hjazidopine for binding
to P-gp. as indicated. The total reaction volumes were 50gil.
Membranes and drug were allowed to reach equilibrium
binding for 20 min in the dark and then irradiated with UV
light (265 nm) for 25 min on a transilluminator (LKB
Instruments). Membranes were labelled with [3H]tamoxifen
aziridine by incubation at 25°C with 0.84JLm labelled drug.R Cda adCF H -
The reactions were stopped by the addition of 2 ml of ice-
cold labelling buffer and membranes were pelleted by centri-
fugation at 120000g in a Beckman TL-100 ultracentrifuge
for 15 min at 4'C. Pellets were solubilised in Laemmli sample
buffer and proteins separated on a 6% sodium dodecylsul-
phate (SDS)-polyacrylamide gel The gels were treated with
Amplify (Amersham, UK), dried onto filter paper, and
labeLled proteins visualised by autoradiography.
Drug bindig toplasma membranes
Drug binding to plasma membranes was assayed using a
rapid filtration assay as previously described (Cfaghan and
Riordan, 1993). Briefly, membranes (404) g of total protein)
were incubated with either [Hjtamoxifen (50nM) or
[3Hlvinblastine (55 nM), and any appropriate unlabelled com-
peting drug, in a buffer composed of 0.01 M Tris pH 7.4,
0.25 M sucrose, 5 mM magnesum chloride. After 60min
incubation at 25'C samples were filtered by light suction
through 0.25gm nitrocellulose filters and washed with ice-
cold buffer (4ml) in a Millipore multichannel filtration
manifold. Filters were added to Ready Protein (Amersham,
UK) scintillation fluid and counted for radioactivity. Non-
specific binding to plasma membranes was defined as the
binding detected in the presence of a 2000-fold excess of
unlabelled drug. Binding to nitrocellulose filters did not
exceed 5-10% of total radioactivity added.
Drug accwnulation assay
Accumulation of [3H]tamoxifen in cell monolayers was
assayed using previously published methods (Cano-Gauci
and Riordan, 1987). Briefly, cells were grown as monolayers
on 60 x 15 mm tissue culture plates to a density of approx-
imately 2.5 x 10'cells per plate. To determine the time course
of drug accumulation, [3Hltamoxifen (0.15 5iCi) was mixed
with unlabelled tamoxifen to a final concentration of 20JM
and added to each plate. Cells were harvested after the
appropriate time points and the amount of radioactivity
acu:mulated determined by scintillation counting.
For [3Hjvinblastine accumulation, labelled drug (0.6pCi)
was added to each plate together with unlabelled drug to a
final vinblastine concentration of 21 nM. Tamoxifen was
added as a competing agent in the concentration range
0-60g-M. Cels were harvested and treated as above.
higher than values reported for vinblastine (Yusa and Tsuro,
1989) and azidopine (Tamai and Safa, 1991), but similar to
those reported for daunomycin and morphine (Callaghan
and Riordan, 1993).
Tamoxifen inhibits the binding ofvinblastine to P-gp
expressing membranes
Vinblastine is a cytotoxic drug which binds to P-gp and is a
transported substrate. The ability of tamoxifen to displace
the specific binding of [3HJvinblastine to KBV-1 membranes
is shown in Figure 2. About 20.1 ± 0.9% of the total [3H]
vinblasine added to the membranes was bound. For P-gp-
expressing cells, 81 ± 2% of this binding was specific, as
defined by its sensitivity to a 2000-fold excess of unlabeLled
vinblastine. In contrast, no specific binding could be detected
for membranes from non-P-gp-expressing KB3-1 cells (data
not shown). Tamoxifen concentrations of 10gM were suffi-
cient to displace approximately 50% of the specific binding
of vinblasutie to P-gp-containing membranes. This implies
that tamoxifen and vinblastine bind to a common site in
these membranes. The ability of tamoxifen to displace vin-
blastine binding compares favourably with that reported for
verapamil and other calcium channel blockers.
Site of[3HJtamoxifen binding to KBV-1 plasma membranes
To identify the site of specific tamoxifen binding to KBV-1
membranes it was necessary to use affinity labelling tech-
niques. Tamoxifen aziridine, an electrophilic analogue of
tamoxifen, has previously been used to demonstrate the
ability of tamoxifen to bind the oestrogen receptor (Katze-
nellenbogen et al., 1983). We therefore examined the abilities
of [HLtamoxifen aziridine and pH]azidopine to label plasma
membranes from P-gp-expressing and non-expressing cells
(Figure 3). [H]Azidopine has previously been demonstrated
to label P-gp (Safa et al., 1987) and, thus, served as a positive
control. [H]Azidopine strongly labeLW a protein of approx-
imately 180 kDa in membranes from P-gp-expressing cells
which was absent from membranes of non-P-gp-expressing
cells (Figure 3a). Immunoppitation with the monoclonal
antibody C219 showed that the 180kDa peptide was P-gp
(data not shown). The 180 kDa protein present only in mem-
branes from P-gp expressing cells was also labelled by [H1
tamoxifen aziridine. Thus, a significant proportion of the
increased binding capacity of KBV-1 membranes to tamox-
ifen (Figure 1) appears to be due to P-gp. Labelling with the
Results
[3H]Tamoxifen binding toplasma membranesfrom KB cells
[HjTamoxifen displayed specific and saturable binding to
plasma membranes isolated from P-gp-expressing (KBV-1)
and non-expressing (KB3-1) cell lines (Figure 1). Of the total
amount of [H]tamoxifen added, about 85% was associated
with the membranes of either cell type. Specific binding was
defined as the binding sensitive to the addition of a 2000-fold
excess of unlabelled tamoxifen. For P-gp-expressing cells
38.7 ± 2.4% of total binding was specific, while for the non
P-gp-expressing cells specific binding accounted for only
5-10 I% of the total. Thus, a significant amount of the
tamoxifen appears to associate non-specifically with the lipid
phase. Non-linear, least-squares regression of the binding
isotherms of [HJtamoxifen to KBV-1 and KB31 membranes
gave binding capacities of 35.4±8.5Spmolmg- (n=5) and
11.1 ± 1.5lmolmg-' (n = 2) respectively. Thus P-gp-contain-
ing membranes have a 3.2-fold greater binding capacity for
VH]tamoxifen than non-Pgp-containing membranes. Tamox-
ifen aziridine binds to several proteins other than P-gp (see
Figures 4 and 5 below) in KBV-1 and KB3-I cells, suggesting
multiple plasma membrane targets for tamoxifen. Nonethe-
less, the significant difference in binding capacity between
KBV-1 and KB34 suggests that the drug binds to P-gp. The
dissociation constant for specific [3Hjtamoxifen binming to
KBV-I membranes was 17.3 ± 1.9 M (n= 5), which is
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Fugwe 1 The specific bndg of[Hjtamoxifen to plasna mem-
branes isolated from KBV-1 (0) and KB3-1 (0) cells. [H}]
Tamoxifen binding was masured after 60 min at room temper-
ature in 1Omm Tns-HCI, 0.25 m sucrose and 5m magnium
chloride. Specific binding was determined by subtracing the
amount of tamoxifen bound in the presence ofa 2000-fold excess
of unlabeled tamoxifen. Each point represents the mean ± s.em.
of at least six independent experiments.
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Figure 2 Tamoxifen inhibits the specific binding of [3H1-
vinblastine to plasma membranes from P-gp-expressing KBV-1
cells. Membranes (40 Lg of protein) were incubated with 55 nM
[3Hjvinblastine and the indicated amount of tamoxifen for 60 min
at room temperature. Data are expressed as a percentage of the
specific binding of vinblastine measured in the absence of com-
peting drug. Each point represents the mean ± s.e.m. of at least
four independent experiments.
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Fge 4 Displacement of [3H]tamoxifen aziridine labelling of
P-glycoprotein. Membranes (40gg) were labelled with 0.85 ILM
[3Hltamoxifen aziridine in the absence or presence of competing
drug at room temperature for 60min. Following solubilization,
40 lg of each sample was electorphoresed on a 6% SDS-poly-
acrylamide gel and subsequently autoradiographed. Tamoxifen
aziridine was in the presence of: (A) no competing drug; (B)
0.1ILM vinblastine; (C) I gM vinblastine; (D) 1O LM vinblastine;
(E) 1OO M vinblastine; and (F) 100 AM tamoxifen.
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Figue 3 Photoaffinity labelling of plasma membranes by [3H-
azidopine (a) and [3H]tamoxifen azinrdine (b). Membranes were
from non-P-gp-expressing KB3-l cells (lanes A) and P-gp-
expressing KBV-1 cells (lanes B). Following labelling and
solubilisation, 40 iLg of each sample was electrophoresed on a 6%
SDS-polyacrylamide gel and labelled protein visualised by
autoradiography.
tamoxifen analogue was not as sensitive as with azidopine
and may reflect a lower affinity of this compound for its
binding site in the membranes.
Two smaller (50 and 100 kDa) polypeptides were also
labelled by [3Hlazidopine. These two polypeptides are prob-
ably proteolytic fragments of P-gp since they were detected
by the anti-Pgp antibody C219 (data not shown). Several
proteins not specific to P-gp-expressing cells were also weakly
labelled by both [3H]azidopine and [3H]tamoxifen aziridine.
This was not unexpected since the targets for [3Hlazidopine
and [3H]tamoxifen aziridine are reactive functional groups on
proteins such as methionines and cysteines (Peters and
Richards, 1977).
Tarnoxifen inhibits the binding ofother compounds to P-gp
Affinity labelling techniques were used to demonstrate that
tamoxifen interacts with the same binding site(s) on P-gp as
vinca alkaloids on calcium channel blockers. The ability of
vinblastine (0.1-100 M) and tamoxifen (1OOI1M) to displace
the binding of [3HJtamoxifen aziridine to KBV-1 membranes
is shown in Figure 4. The displacement of tamoxifen
aziridine from P-gp by vinblastine was dose dependent and
almost complete at 100 iLM. In addition, we studied the
ability of tamoxifen to displace the specific photoaffinity
labelling of P-gp by [3Hjazidopine (Figure 5). Azidopine is a
Figue 5 Displacement of [3Hlazidopine labelling of P-gp. Mem-
branes (40jLg) were labelled with 45 nM [3H,azidopine in the
absence or presence of competing drug at room temperature for
60 min. Following solubilisation, 40jg of each sample was
electrophoresed on a 6% SDS-polyacrylamide gel and subse-
quently autoradiographed. Labelling was in the presence of: (A)
no competing drug; (B) I iLM tamoxifen; (C) 10IM tamoxifen;
(D) 501M tamoxifen; (E) 100tLM tamoxifen; (F) 501LM vinblas-
tine and (G) 50 jIM veraparnil.
high-affinity substrate for P-gp with a Kd of 1.5 1iM (Tamai
and Safa, 1991). Labelling of Pgp by azidopine was
significantly reduced by 10JM tamoxifen and completely
inhibited by 50 jM tamoxifen. Tamoxifen had a similar IC50
for displacing both [3H]vinblastine binding and [3Hlazidopine
labelling of P-gp. An equimolar concentration of vinblastine
displayed similar potency in displacing azidopine binding.
Thus, tamoxifen appears to interact at the same binding site
on P-gp as vinblastine and the calcium channel blocker
azidopine. In contrast, a similar concentration of verapamil,
an MDR reversing agent, did not appreciably reduce
photolabelling by azidopine.
Effects oftwnoxifen on [3H]vinblastine accumulation in KB
cells
Tamoxifen reverses drug resistance in P-gp-expressing cells.
As tamoxifen binds to P-gp, it seemed likely that it reverses
drug resistance by inhibiting drug transport. To address this
point we studied the effects of tamoxifen on the accumulation
of [3Hlvinblastine (21 nM) in P-gp-expressing (KBV-1) and
non-expressing (KB3-1) cell lines (Figure 6). The results ex-
pressed as the increase in vinblastine accumulation observed
in the presence of tamox.ifen above the levels observed in the
absence of tamoxifen. In the absence of tamoxifen, non-Pgp-
expressing KB3-1 cells accumulated approximately 6-fold-inaclon o tumzdkn with P.*coriuin
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Fge 6 Effect of tamoxifen on [3Hlvinblastine accumulation by
KB3-1 (0) and KBV-1 (0) cells. Cells were incubated with
21 nm vinblastine for 60 min at 3TC in the presence of the
indicated concentration of tamoxifen. Values are expressed as the
increase in vinblastine accumulation compared with that obtained
in the absence of tamoxifen. Each point represents the mean
s.e.m. of at least three independent experiments.
more (3Hjvinblastine (12.1 ± 2.4 pmol mg-') than the P-gp-
expressing KBV-1 cells (1.89 ± 0.25 pmol mg-'), as expected.
Tamoxifen had no appreciable effect on [3H]vinblastine
accumulation in non-P-gp-expressing cells at concentrations
up to 60 WM. However, in P-gp expressing KBV-1 cells,
tamoxifen caused a dose-dependent increase in the accumula-
tion of [3HJvinblastine. The amount of [3H]vinblastine
accumulated in KBV-1 cells at 60 M tamoxifen was equiva-
lent to approximately 50% of the level in drug sensitive
KB3-1 cells. These data show that tamoxifen impairs the
P-gp-dependent transport of vinblastine.
Tanoxifen is not itself transportedbk' P-gp
The accumulation of [3H]tamoxifen by P-gp-expressing and
non-expressing cells is shown in Figure 7. In both cell lines
there was a rapid initial accumulation of tamoxifen which
plateaued by approximately 30 min. There was no significant
difference in the steady-state accumulation of labelled tamox-
ifen between the two cell lines. This is in contrast to
[3Hlvinblastine, which as reported in the preceding section,
has a 6-fold lower accumulation in KBV-1 cells than in KB-1
cells. Tamoxifen is highly lipophilic, and approximately 80%
of the total counts added were associated with the cells. The
data above, which show that a similar proportion of [3H}
tamoxifen associates with isolated plasma membranes,
indicate that a significnt proportion of the tamoxifen is
non-speifically bound to the cell membrane rather than
being accumulated intracellularly. In plasma, tamoxifen is
extensively bound to proteins which alter its distribution
between cells and serum (Chaterjee and Harris, 1990). The
addition of albumin (0-2%, w/v) to the transport medium
caused a fall (30% at a concentration of 1.0%, w/v) in the
amount of tamoxifen bound by both cell lines (data not
shown). However, there was still no significant difference in
accumulation between the two cell lines under these condi-
tions. Thus, tamoxifen does not appear to be transported by
P-gp despite its ability to bind to the protein and displace the
binding of transported substrates.
Diso
Tamoxifen exerts tumoristatic effects through its interaction
with the oestrogen receptor. Tamoxifen has generally been
assumed to be relatively specific in its interactions with cel-
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Figue 7 Time course of [3H]tamoxifen accumulation by KB3-1
(0) and KBV-1 (0) cells. Cells were incubated with 20 tLM
tamoxifen for the indicated time periods at 37C. Each point
represents the mean ± s.e.m. of at least three independent
experiments.
lular proteins. In this study we identify a new cellular target
for tamoxifen, the multidrug resistance P-glycoprotein. Not
only does tamoxifen bind to P-gp, it inhibits P-gp-mediated
drug transport. This defines the mechanism whereby tamox-
ifen can reverse multidrug resistance. As tamoxifen is well
tolerated at high doses in vivo (Stuart et al., 1992), it may
prove to be a valuable tool in overcoming drug resistance in
neoplastic disorders.
Tamoxifen has been reported to reverse P-glycoprotein-
mediated multidrug resistance in vitro (Ramu et al., 1984;
DeGregorio et al., 1989; Kirk et al., 1993a). The mechanism
by which this is achieved has not been established, although
a recent study suggests an interaction between P-gp and
tamoxifen in oestrogen receptor-positive MCF7' cells
(Leonessa et al., 1994). Many agents which reverse MDR
bind specifically to P-gp and to compete with cytotoxic drugs
for active transport (Cornwell et al., 1987; Safa et al., 1987;
Ryffel et al., 1991). We have shown that tamoxifen also
interacts directly with P-gp. Furthermore, tamoxifen appears
to inhibit drug transport since it dramatically increased vin-
blastine accumulation in P-gp-expressing cells. Thus, it
appears that the reversal of multidrug resistance by tamox-
ifen is due to the interaction of tamoxifen with P-gp and the
consequent inhibition of P-gp-dependent drug transport.
Tamoxifen was shown to displace the specific binding of
azidopine and vinblastine to P-gp. This suggests that tamox-
ifen interacts directly with the drug binding site on P-gp. The
precise nature of this site is unclear. Two regions on P-gp are
labelled by azidopine (Bruggemann et al., 1989, 1992;
Yoshimura et al., 1989), one in each half of the protein.
However, it is believed that these two regions form a single
drug binding site (Bruggeman et al., 1992). It has, however,
been suggested on the basis of binding and competition
studies, that P-gp may have distinct binding sites for vinca
alkaloids and azidopine (Tamai and Safa, 1991). Verapamil is
more efficacious at inhibiting binding to the vinca alkaloid
site. However, the steroid hormone progesterone competes
equally well with either vinca alkaloids or azidopine for
binding to P-gp (Yang et al., 1989). As tamoxifen competes
with both vinblastine and azidopine for binding to P-gp, if
P-gp is able to bind or handle vinca alkaloids and azidopine
differentially, then tamoxifen (like progesterone) must
interfere with both sites/mechanisms.
Compounds which reverse multidrug resistance may pre-
vent drug transport simply by occupying the drug binding
site on P-gp, or by competing directly with cytotoxic drugs
for transport. Many MDR reversing agents, such as verapa-
mil (Cano-Gauci and Riordan, 1987; Yusa and Tsuro, 1989),
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azidopine (Tamai and Safa. 1991). cyclosporin and FK506
(Ueda et al.. 1992). have been reported to be transported by
P-gp. However, we could detect no difference in the abilities
of drug-resistant and drug-sensitive cells to accumulate
tamoxifen. This suggests that tamoxifen is not transported by
P-gp. A previous report has also suggested that tamoxifen is
not a substrate for ATP-sensitive drug efflux in adriamycin-
resistant P388 murine leukaemic cells (Kessel, 1986). The
interaction of tamoxifen with P-gp may be similar to that of
the steroid hormone progesterone. Like tamoxifen, pro-
gesterone inhibits azidopine photolabelling of P-gp (Yang et
al.. 1989) and vinca alkaloid binding to P-gp-containing
plasma membranes (Yang et al., 1990) and increases the
cellular levels of vinblastine (Yang et al.. 1989). yet does not
appear to be a substrate for transport by P-gp (Yang et al.,
1989; Saeki et al.. 1993). Thus, there appear to be two classes
of reversers of P-gp-mediated drug resistance. The first class
consists of compounds which compete with cytotoxic drugs
for binding and transport by P-gp. The second class of
reversers, which includes tamoxifen and progesterone, com-
pete for drug binding, thereby blocking transport of
chemotherapeutic agents. but are not themselves transport-
ed.
In addition to its role in drug resistance, expression of
P-gp is also associated with a cell volume-regulated chloride
channel (Gill et al.. 1992: Valverde et al.. 1992). Tamoxifen is
also a high-affinity inhibitor of this chlonrde channel.
although it is not known whether or not this inhibitory effect
is mediated through the interaction of tamoxifen with P-gp
(Zhang et al.. 1994). The blockage of chloride channels by
tamoxifen in the lens of the eye leads to opacity. suggesting a
molecular mechanism by which tamoxifen might lead to
visual impairment (Zhang et al.. 1994). Together with the
present finding that tamoxifen binds to P-gp. these data
suggest that tamoxifen may interact with a number of func-
tionally important targets. with consequent implications for
the therapeutic use of this anti-cancer drug.
Abbreviatkoa MDR. multidrug resistance: P-gp. P-glycoprotein;
FBS. fetal bovine serum: DMEM. Dulbecco's modified Eagle
medium; PMSF. phenylmethylsulfonyl fluoride: EDTA. ethylenedia-
minetetraacetic acid.
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